• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
BCRX

BCRX

BioCryst Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD8.25

-0.09 (-1.08%)

Rating:B-

Company Profile

CEO

Charles K. Gayer

IPO Date

1994-03-04

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$8.33

Prev. Close

$8.34

Day Low

$8.06

Day High

$8.47

52W Low

$6.00

52W High

$11.23

Market Cap

$1.73B

Volume

4.17M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

44.7%

Avg Negative

17.6%

Avg Neutral

37.6%

News Feed

BioCryst Appoints Dr. Steven Galson to Board of Directors

GlobeNewsWire·8/26/2021·↑ positive

BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic

GlobeNewsWire·8/25/2021·↑ positive

BioCryst Stock Jumps After Pulling Out $200M Equity Raise

Benzinga·8/11/2021
·↓ negative

BioCryst Withdraws Public Offering

GlobeNewsWire·8/10/2021·↓ negative

Why BioCryst Pharmaceuticals Rose 8% on Thursday

The Motley Fool·8/5/2021·↑ positive

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/5/2021·↓ negative

BioCryst Pharma Stock Heads Higher Thursday: Here's Why

Benzinga·8/5/2021·↑ positive

BioCryst to Report Second Quarter 2021 Financial Results on August 5

GlobeNewsWire·7/22/2021·↓ negative

BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price

Seeking Alpha·7/21/2021·↑ positive

BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder

Benzinga·7/15/2021·↑ positive